Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$1.59 - $3.85 $92,526 - $224,043
-58,193 Reduced 83.26%
11,699 $39,000
Q3 2023

Nov 14, 2023

SELL
$3.74 - $5.45 $157,816 - $229,973
-42,197 Reduced 37.65%
69,892 $261,000
Q2 2023

Aug 10, 2023

BUY
$3.79 - $8.3 $98,342 - $215,368
25,948 Added 30.12%
112,089 $478,000
Q1 2023

May 12, 2023

SELL
$5.89 - $10.52 $16,085 - $28,730
-2,731 Reduced 3.07%
86,141 $590,000
Q4 2022

Feb 10, 2023

BUY
$5.69 - $10.07 $19,607 - $34,701
3,446 Added 4.03%
88,872 $704,000
Q3 2022

Nov 01, 2022

BUY
$7.17 - $13.87 $612,504 - $1.18 Million
85,426 New
85,426 $821,000
Q2 2022

Aug 09, 2022

BUY
$5.86 - $13.23 $50,689 - $114,439
8,650 Added 15.93%
62,935 $456,000
Q4 2021

Feb 14, 2022

SELL
$15.81 - $18.99 $41,358 - $49,677
-2,616 Reduced 4.6%
54,285 $866,000
Q2 2021

Aug 11, 2021

BUY
$12.95 - $15.41 $36,609 - $43,564
2,827 Added 5.23%
56,901 $787,000
Q1 2021

May 17, 2021

SELL
$14.42 - $21.39 $106,188 - $157,515
-7,364 Reduced 11.99%
54,074 $790,000
Q4 2020

Feb 16, 2021

SELL
$16.56 - $18.94 $99,558 - $113,867
-6,012 Reduced 8.91%
61,438 $1.07 Million
Q3 2020

Nov 17, 2020

BUY
$17.41 - $19.89 $1.14 Million - $1.3 Million
65,416 Added 3216.13%
67,450 $1.24 Million
Q3 2020

Nov 13, 2020

SELL
$17.41 - $19.89 $1.27 Million - $1.45 Million
-72,860 Reduced 97.28%
2,034 $37,000
Q2 2020

Aug 17, 2020

BUY
$14.43 - $19.16 $1.03 Million - $1.37 Million
71,300 Added 1983.86%
74,894 $1.34 Million
Q4 2019

Feb 11, 2020

BUY
$16.33 - $21.37 $58,690 - $76,803
3,594 New
3,594 $64,000
Q3 2019

Oct 25, 2019

SELL
$16.3 - $23.37 $110,416 - $158,308
-6,774 Closed
0 $0
Q2 2019

Jul 31, 2019

BUY
$13.1 - $22.1 $44,199 - $74,565
3,374 Added 99.24%
6,774 $0
Q3 2017

Nov 09, 2017

BUY
$11.1 - $14.5 $37,740 - $49,300
3,400
3,400 $46,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $115M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.